Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $32.50 Consensus Price Target from Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have received an average recommendation of “Buy” from the nine ratings firms that are currently covering the firm, MarketBeat reports. Eight equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $32.50.

Several research firms have recently weighed in on CPRX. Stephens restated an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Robert W. Baird lifted their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, Bank of America reiterated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th.

Insider Activity

In related news, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in CPRX. Steward Partners Investment Advisory LLC acquired a new position in Catalyst Pharmaceuticals during the 4th quarter worth approximately $27,000. Park Square Financial Group LLC purchased a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at approximately $29,000. Farther Finance Advisors LLC lifted its stake in Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 1,495 shares in the last quarter. Larson Financial Group LLC lifted its stake in Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 2,994 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at approximately $65,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX opened at $22.60 on Monday. The company has a market cap of $2.74 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84. The stock’s 50 day simple moving average is $22.34 and its 200-day simple moving average is $21.57. Catalyst Pharmaceuticals has a 1-year low of $14.47 and a 1-year high of $24.64.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.